

Question n°2

Quels sont les mécanismes en général ?

Comment expliquer les expressions cliniques gravissimes ?

PM. Mertes¹, M. Pinaud²

¹Laboratoire d'explorations fonctionnelles respiratoires et d'allergologie, hôpital Maison Blanche, 45 rue Cognacq Jay, 51092 Reims cedex, ²département d'anesthésie et réanimations, CHU, Hôtel-Dieu, 44093 Nantes cedex 01

RÉFÉRENCES

1. Watkins J, Ward AM, Thornton JA. Adverse reactions to intravenous induction agents [letter]. *Br Med J* 1978;2:1431.
2. Watkins J. Markers and mechanisms of anaphylactoid reactions. *Monogr Allergy* 1992;30:108-29.
3. Fisher M, Baldo BA. Anaphylaxis during anaesthesia: current aspects of diagnosis and prevention. *Eur J Anaesthesiol* 1994;11:263-84.
4. Brown AF. Anaphylactic shock: mechanisms and treatment [see comments]. *J Accid Emerg Med* 1995;12:89-100.
5. McKinnon RP, Wildsmith JA. Histaminoid reactions in anaesthesia. *Br J Anaesth* 1995;74:217-28.
6. Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. *Mol Immunol* 1983;20:1393-400.
7. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. *Nature* 1983;306:262-4.
8. Fisher MM, Harle DG, Baldo BA. Anaphylactoid reactions to narcotic analgesics. *Clin Rev Allergy* 1991;9:309-18.
9. Paton WDM. Histamine release by compounds of simple chemical structure. *Pharmacological Review* 1957;9:269-328.
10. Lorenz W, Doenicke A, Feifel G, Messmer K, Meier R, Bennesch L, et al. Histamine release in man by propanidid (Epontol), gelatin (Haemaccel), histalog, pentagastrin and insulin. *Naunyn Schmiedeberg's Arch Pharmacol* 1970;266:396-7.
11. Genovese A, Stellato C, Marsella CV, Adt M, Marone G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. *Int Arch Allergy Immunol* 1996;110:13-22.

12. Stellato C, Casolaro V, Ciccarelli A, Mastronardi P, Mazzarella B, Marone G. General anaesthetics induce only histamine release selectively from human mast cells. *Br J Anaesth* 1991;67:751-8.
13. Stellato C, de Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G. Heterogeneity of human mast cells and basophils in response to muscle relaxants. *Anesthesiology* 1991;74:1078-86.
14. Marone G, Stellato C, Mastronardi P, Mazzarella B. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. *Ann Fr Anesth Réanim* 1993;12:116-25.
15. Findlay SR, Dvorak AM, Kagey-Sobotka A, Lichtenstein LM. Hyperosmolar triggering of histamine release from human basophils. *J Clin Invest* 1981;67:1604-13.
16. Scott RP, Savarese JJ, Basta SJ, Sunder N, Ali HH, Gargarian M, et al. Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response. *Br J Anaesth* 1985;57:550-3.
17. Lorenz W, Doenicke A. Anaphylactoid reactions and histamine release by barbiturate induction agents: clinical relevance and patho-mechanisms [editorial]. *Anesthesiology* 1985;63:351-2.
18. Moss J, Rosow CE. Histamine release by narcotics and muscle relaxants in humans. *Anesthesiology* 1983;59:330-9.
19. Harle DG, Baldo BA, Fisher MM. Inhibition of histamine-N-methyltransferase activity by neuromuscular blocking drugs. *Agents Actions* 1985;17:27-31.
20. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. *Anesthesiology* 1991;75:945-9.
21. Laroche D, Lefrancois C, Gérard JL, Dubois F, Vergnaud MC, Guéant JL, et al. Early diagnosis of anaphylactic reactions to neuromuscular blocking drugs. *Br J Anaesth* 1992;69:611-4.
22. Laroche D, Dubois F, Lefrancois C, Vergnaud MC, Gérard JL, Soufarapis H, et al. Marqueurs biologiques précoces des réactions anaphylactoïdes peranesthésiques. *Ann Fr Anesth Réanim* 1992;11:613-8.
23. Aimone-Gastin I, Guéant JL, Laxenaire MC, Monneret-Vautrin DA. Pathogenesis of allergic reactions to anaesthetic drugs. *Int J Immunopathol Pharmacol* 1997;10:193-6.
24. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* 1991;351:290-6.

25. de Weck AL. Immunochemical particularities of anaphylactic reactions to compounds used in anesthesia. *Ann Fr Anesth Réanim* 1993;12:126-30.
26. Vervloet D, Arnaud A, Vellieux P, Kaplanski S, Charpin J. Anaphylactic reactions to muscle relaxants under general anesthesia. *J Allergy Clin Immunol* 1979;63:348-53.
27. Baldo BA, Fisher MM. Mechanisms in IgE-dependent anaphylaxis to anesthetic drugs. *Ann Fr Anesth Réanim* 1993;12:131-40.
28. Romagnoli P, Labhardt AM, Sinigaglia F. Selective interaction of Ni with an MHC-bound peptide. *EMBO J* 1991;10:1303-6.
29. van den Broeke LT, Heffler LC, Tengvall-Linder M, Nilsson JLG, Karlberg AT, Scheynius A. Direct Ni²⁺ antigen formation on cultured human dendritic cells. *Immunology* 1999;96:578-85.
30. Laxenaire MC. Epidémiologie des réactions anaphylactoides peranesthésiques. Quatrième enquête multicentrique (juillet 1994-décembre 1996). Le Groupe d'études des réactions anaphylactoides peranesthésiques. *Ann Fr Anesth Réanim* 1999;18:796-809.
31. Assem ESK. Anaphylactoid reactions to neuromuscular blockers : major role of IgE antibodies and possible contribution of IgE-independent mechanisms. In: Assem ESK, Ed. *Allergic reactions to anaesthetics. Clinical and basic aspects. Monogr Allergy ed. Basel: Karger; 1992. p. 24-53.*
32. Daeron M, Voisin GA. H-2 antigens, on mast cell membrane, as target antigens for anaphylactic degranulation. *Cell Immunol* 1978;37:467-72.
33. Moneret-Vautrin DA, Guéant JL, Kamel L, Laxenaire MC, el Kholty S, Nicolas JP. Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. *J Allergy Clin Immunol* 1988;82:745-52.
34. Birnbaum J, Vervloet D. Mechanisms of anaphylactic reactions to muscle relaxants: role of allergenic determinants. *Allergy to muscle relaxants. Monogr Allergy* 1992;30:15-23.
35. Didier A, Cador D, Bongrand P, Furstoss R, Fourneron P, Senft M, et al. Role of the quaternary ammonium ion determinants in allergy to muscle relaxants. *J Allergy Clin Immunol* 1987;79:578-84.
36. Birnbaum J, Vervloet D. Allergy to muscle relaxants. *Clin Rev Allergy* 1991;9:281-93.
37. Fisher MM, More DG. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. *Anaesth Intensive Care* 1981;9:226-34.
38. Baldo BA, Fisher MM, Harle DG. Allergy to thiopentone. *Clin Rev Allergy* 1991;9:295-308.

39. Baldo BA, Pham NH. Structure--activity studies on drug-induced anaphylactic reactions. *Chem Res Toxicol* 1994;7:703-21.
40. Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Guéant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan) [see comments]. *Anesthesiology* 1992;77:275-80.
41. Breiteneder H, Scheiner O. Molecular and immunological characteristics of latex allergens. *Int Arch Allergy Immunol* 1998;116:83-92.
42. Winton GB. Anesthesia for dermatologic surgery. *J Dermatol Surg Oncol* 1988;14:41-54.
43. Ruzicka T, Gerstmeier M, Przybilla B, Ring J. Allergy to local anesthetics: comparison of patch test with prick test and intradermal test results. *J Am Acad Dermatol* 1987;16:1202-8.
44. Canfield D, Gage T. A guideline to local anesthetic allergy testing. *Anesth Prog* 1987;34:157-63.
45. Fine P, Dingman DL. Hypersensitivity dermatitis following suction-assisted lipectomy: a complication of local anesthetics. *Ann Plast Surg* 1988;20:573-5.
46. Simon R. Adverse reactions to drug additives. *J Allergy Clin Immunol* 1984;74:623-30.
47. Doms-Goosens A, de Alam AG, Degreef H, Kochuyt A. Local anesthetic intolerance due to metabisulfite. *Contact Dermatitis* 1989;20:124-6.
48. Enjeti S, Bleecker ER, Smith PL, Rabson J, Permutt S, Traystman RJ. Hemodynamic mechanisms in anaphylaxis. *Circ Shock* 1983;11:297-309.
49. Wagner EM, Mitzner WA, Bleecker ER. Peripheral circulatory alterations in canine anaphylactic shock. *Am J Physiol* 1986;251:H934-40.
50. Correa E, Mink S, Unruh H, Kepron W. Left ventricular contractility is depressed in IgE-mediated anaphylactic shock in dogs. *Am J Physiol* 1991;260:H744-51.
51. Martin TR, Ando A, Takeishi T, Katona IM, Drazen JM, Galli SJ. Mast cells contribute to the changes in heart rate, but not hypotension or death, associated with active anaphylaxis in mice. *J Immunol* 1993;151:367-76.
52. Mitsuhashi H, Hasome N, Saitoh J, Takeuchi H, Horiguchi Y, Shimizu R. Evaluation of left ventricular diastolic function in IgE-mediated anaphylaxis in dogs. *Acta Anaesthesiol Scand* 1995;39:791-6.
53. Shibamoto T, Wang HG, Tanaka S, Miyahara T, Koyama S. Participation of nitric oxide in the sympathetic response to anaphylactic hypotension in anesthetized dogs. *Neurosci Lett* 1996;212:99-102.

54. Beaupre PN, Roizen MF, Cahalan MK, Alpert RA, Cassorla L, Schiller NB. Hemodynamic and two-dimensional transesophageal echocardiographic analysis of an anaphylactic reaction in a human. *Anesthesiology* 1984;60:482-4.
55. Nicolas F, Villers D, Blanloeil Y. Hemodynamic pattern in anaphylactic shock with cardiac arrest. *Crit Care Med* 1984;12:144-5.
56. Silverman HJ, Van Hook C, Haponik EF. Hemodynamic changes in human anaphylaxis. *Am J Med* 1984;77:341-4.
57. Levy JH. Anaphylactic/anaphylactoid reactions during cardiac surgery. *J Clin Anesth* 1989;1:426-30.
58. Kapin MA, Ferguson JL. Hemodynamic and regional circulatory alterations in dog during anaphylactic challenge. *Am J Physiol* 1985;249:H430-7.
59. Yamaguchi Y, Shibamoto T, Hayashi T, Saeki Y, Tanaka S. Hepatic vascular response to anaphylaxis in isolated canine liver. *Am J Physiol* 1994;267:R268-74.
60. Tang W, Weil MH, Sun S, Noc M, Gazmuri RJ, Bisera J. Gastric intramural PCO₂ as monitor of perfusion failure during hemorrhagic and anaphylactic shock. *J Appl Physiol* 1994;76:572-7.
61. Bristow MR, Ginsburg R, Harrison HC. Histamine and the human heart: the other receptor system. *Am J Cardiol* 1982;49:249-51.
62. Reinhardt D, Borchard U. H₁-receptor antagonists: comparative pharmacology and clinical use. *Klin Wochenschr* 1982;60:983-90.
63. Kaliner M, Shelhamer JH, Ottesen EA. Effects of infused histamine: correlation of plasma histamine levels and symptoms. *J Allergy Clin Immunol* 1982;69:283-9.
64. Vigorito C, Russo P, Picotti GB, Chiariello M, Poto S, Marone G. Cardiovascular effects of histamine infusion in man. *J Cardiovasc Pharmacol* 1983;5:531-7.
65. Pavek K, Wegmann A, Nordstrom L, Schwander D. Cardiovascular and respiratory mechanisms in anaphylactic and anaphylactoid shock reactions. *Klin Wochenschr* 1982;60:941-7.
66. Morel DR, Zapol WM, Thomas SJ, Kitain EM, Robinson DR, Moss J, et al. C₅a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. *Anesthesiology* 1987;66:597-604.
67. Morel DR, Skoskiewicz M, Robinson DR, Bloch KJ, Hoaglin DC, Zapol WM. Leukotrienes, thromboxane A₂, and prostaglandins during systemic anaphylaxis in sheep. *Am J Physiol* 1991;261:H782-92.
68. Levy JH. The human inflammatory response. *J Cardiovasc Pharmacol* 1996;27 Suppl 1:S31-7.

69. Mink SN, Becker A, Unruh H, Kepron W. Effects of anaphylaxis mediators on partitioned pulmonary vascular resistance during ragweed shock in dogs. *J Appl Physiol* 1998;84:782-90.
70. Fahmy NR. Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine. *Anesthesiology* 1981;55:329-31.
71. Moss J, Fahmy NR, Sunder N, Beaven MA. Hormonal and hemodynamic profile of an anaphylactic reaction in man. *Circulation* 1981;63:210-3.
72. Levi R. Cardiac anaphylaxis: models, mediators, mechanisms and clinical considerations. In: Levi R, Ed. *Human inflammatory disease. Clinical Immunology*. Toronto: B.C. Decker Inc; 1988. p. 95-105.
73. Kanny G, Maria Y, Mentre B, Moneret-Vautrin DA. [Case report: recurrent anaphylactic shock to radiographic contrast media. Evidence supporting an exceptional IgE-mediated reaction]. *Allerg Immunol (Paris)* 1993;25:425-30.
74. Duffy BL, Harding JN, Fuller WR, Peake SL. Cardiac arrest following Haemacel [see comments]. *Anaesth Intensive Care* 1994;22:90-2.
75. Jacobsen J, Secher NH. Slowing of the heart during anaphylactic shock. A report of five cases. *Acta Anaesthesiol Scand* 1988;32:401-3.
76. Assem ES. Anaphylactic reactions affecting the human heart. *Agents Actions* 1989;27:142-5.
77. Petsas AA, Kotler MN. Electrocardiographic changes associated with penicillin anaphylaxis. *Chest* 1973;64:66-9.
78. Levine HD. Acute myocardial infarction following wasp sting. Report of two cases and critical survey of the literature. *Am Heart J* 1976;91:365-74.
79. Antonelli D, Koltun B, Barzilay J. Transient ST segment elevation during anaphylactic shock. *Am Heart J* 1984;108:1052-4.
80. Engrav MB, Zimmerman M. Electrocardiographic changes associated with anaphylaxis in a patient with normal coronary arteries. *West J Med* 1994;161:602-4.
81. Booth BH, Patterson R. Electrocardiographic changes during human anaphylaxis. *Jama* 1970;211:627-31.
82. Stein I, Wecksell I. Cardiac disease accompanying allergic drug reactions. *J Allergy* 1970;45:48-54.
83. Wagdi P, Mehan VK, Burgi H, Salzmann C. Acute myocardial infarction after wasp stings in a patient with normal coronary arteries. *Am Heart J* 1994;128:820-3.

84. Druck MN, Johnstone DE, Staniloff H, McLaughlin PR. Coronary artery spasm as a manifestation of anaphylactoid reaction to iodinated contrast material. *Can Med Assoc J* 1981;125:1133-5.
85. Austin SM, Barooah B, Kim CS. Reversible acute cardiac injury during cefoxitin-induced anaphylaxis in a patient with normal coronary arteries. *Am J Med* 1984;77:729-32.
86. Jacobs RL, Rake GW, Jr., Fournier DC, Chilton RJ, Culver WG, Beckmann CH. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. *J Allergy Clin Immunol* 1981;68:125-7.
87. Hannaway PJ, Hopper GD. Severe anaphylaxis and drug-induced beta-blockade [letter]. *N Engl J Med* 1983;308:1536.
88. Laxenaire MC, Torrens J, Moneret-Vautrin DA. Choc anaphylactoïde mortel chez un malade traité par bêta-bloquants. *Ann Fr Anesth Réanim* 1984;3:453-5.
89. Zaloga GP, DeLacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. *Ann Intern Med* 1986;105:65-6.
90. Moneret-Vautrin DA, Kanny G, Faller JP, Levan D, Kohler C. Choc anaphylactique grave avec arrêt cardiaque au café et a la gomme arabique, potentialisé par un collyre bêta-bloquant. *Rev Med Interne* 1993;14:107-11.
91. Waldhausen E, Keser G, Marquardt B. Colloids, anaphylaxis, and the heart [letter]. *Lancet* 1988;2:220.
92. Otero E, Onufer JR, Reiss CK, Korenblat PE. Anaphylaxis-induced myocardial depression treated with amrinone [letter]. *Lancet* 1991;337:682.
93. Raper RF, Fisher MM. Profound reversible myocardial depression after anaphylaxis. *Lancet* 1988;1:386-8.
94. Javeed N, Javeed H, Javeed S, Moussa G, Wong P, Rezai F. Refractory anaphylactoid shock potentiated by beta-blockers. *Cathet Cardiovasc Diagn* 1996;39:383-4.
95. Delage C, Mullick FG, Irely NS. Myocardial lesions in anaphylaxis. A histochemical study. *Arch Pathol* 1973;95:185-9.
96. Pavek K. Anaphylactic shock in the monkey: its hemodynamics and mediators. *Acta Anaesthesiol Scand* 1977;21:293-307.
97. Pavek K, Piper PJ, Smedegard G. Anaphylatoxin-induced shock and two patterns of anaphylactic shock: hemodynamics and mediators. *Acta Physiol Scand* 1979;105:393-403.
98. Felix SB, Baumann G, Berdel WE. Systemic anaphylaxis--separation of cardiac reactions from respiratory and peripheral vascular events. *Res Exp Med [Berl]* 1990;190:239-52.

99. Felix SB, Baumann G, Hashemi T, Niemczyk M, Ahmad Z, Berdel WE. Characterization of cardiovascular events mediated by platelet activating factor during systemic anaphylaxis. *J Cardiovasc Pharmacol* 1990;15:987-97.
100. Felix SB, Baumann G, Niemczyk M, Ahmad Z, Hashemi T, Berdel WE. Effects of platelet-activating factor on beta- and H₂-receptor-mediated increase of myocardial contractile force in isolated perfused guinea pig hearts. *Res Exp Med* 1991;191:1-9.
101. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34⁺ bone marrow progenitor cells. *J Immunol* 1991;146:1410-5.
102. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. *Blood* 1992;80:2237-45.
103. Nilsson G, Forsberg K, Bodger MP, Ashman LK, Zsebo KM, Ishizaka T, et al. Phenotypic characterization of stem cell factor-dependent human foetal liver-derived mast cells. *Immunology* 1993;79:325-30.
104. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, et al. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E₂ from cord blood mononuclear cells. *J Immunol* 1996;157:343-50.
105. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34⁺, c-kit⁺, and expresses aminopeptidase N (CD13). *Blood* 1999;94:2333-42.
106. Stenton GR, Vliagoftis H, Befus AD. Role of intestinal mast cells in modulating gastrointestinal pathophysiology. *Ann Allergy Asthma Immunol* 1998;81:1-11.
107. Marone G, Patella V, de Crescenzo G, Genovese A, Adt M. Human heart mast cells in anaphylaxis and cardiovascular disease. *Int Arch Allergy Immunol* 1995;107:72-5.
108. Patella V, Marino I, Lamparter B, Genovese A, Adt M, Marone G. Immunologic and non-immunologic release of histamine and tryptase from human heart mast cells. *Inflamm Res* 1995;44 Suppl 1:S22-3.
109. Patella V, Genovese A, Marone G. What are human heart mast cells for? *Chem Immunol* 1995;62:171-86.
110. Marone G, Spadaro G, De Marino V, Aliperta M, Triggiani M. Immunopharmacology of human mast cells and basophils. *Int J Clin Lab Res* 1998;28:12-22.
111. Schwartz L, Huhh T. Biology of mast cells and basophiles. In: Middleton E, Reed C, Ellis E, Adkinson N, Yunginger J, Busse W, Eds. *Allergy : principles and practices*. St Louis: Mosby-Year Book; 1993. p. 156-68.

112. Patella V, Ciccarelli A, Lamparter-Schummert B, de Paulis A, Adt M, Marone G. Heterogeneous effects of protamine on human mast cells and basophils. *Br J Anaesth* 1997;78:724-30.
113. Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. *Br J Anaesth* 1998;80:26-9.
114. Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A. Immunological characterization and functional importance of human heart mast cells. *Immunopharmacology* 1995;31:1-18.
115. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II- forming enzyme in the human heart [published erratum appears in *J Biol Chem* 1991 Jun 25;266:12114]. *J Biol Chem* 1990;265:22348-57.
116. Graver LM, Robertson DA, Levi R, Becker CG, Weksler BB, Gay WA. IgE-mediated hypersensitivity in human heart tissue: histamine release and functional changes. *J Allergy Clin Immunol* 1986;77:709-14.
117. Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K, et al. Interleukin 4 is localized to and released by human mast cells. *J Exp Med* 1992;176:1381-6.
118. Moller A, Lippert U, Lessmann D, Kolde G, Hamann K, Welker P, et al. Human mast cells produce IL-8. *J Immunol* 1993;151:3261-6.
119. Bradding P, Okayama Y, Howarth PH, Church MK, Holgate ST. Heterogeneity of human mast cells based on cytokine content. *J Immunol* 1995;155:297-307.
120. Bradding P. Human mast cell cytokines. *Clin Exp Allergy* 1996;26:13-9.
121. Patella V, Marino I, Lamparter B, Arbustini E, Adt M, Marone G. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. *J Immunol* 1995;154:2855-65.
122. Schwartz LB, Austen KF. Structure and function of the chemical mediators of mast cells. *Prog Allergy* 1984;34:271-321.
123. Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, et al. Highly potent and selective ligands for histamine H₃-receptors. *Nature* 1987;327:117-23.
124. Ichinose M, Stretton CD, Schwartz JC, Barnes PJ. Histamine H₃-receptors inhibit cholinergic neurotransmission in guinea-pig airways. *Br J Pharmacol* 1989;97:13-5.
125. Ichinose M, Barnes PJ. Inhibitory histamine H₃-receptors on cholinergic nerves in human airways. *Eur J Pharmacol* 1989;163:383-6.
126. Garbarg M, Schwartz JC. The histamine H₃ receptor: pharmacology and potential therapeutic applications. *Ann Fr Anesth Réanim* 1993;12:114-5.

127. Ginsburg R, Bristow MR, Stinson EB, Harrison DC. Histamine receptors in the human heart. *Life Sci* 1980;26:2245-9.
128. Watkins J, Thornton JA. Immunological and non-immunological mechanisms involved in adverse reactions to drugs. *Klin Wochenschr* 1982;60:958-64.
129. Cooper DJ, Thompson CR, Walley KR, Gillis RP, Wolinski-Walley PE, Schellenberg RR. Histamine decreases left ventricular contractility in normal human subjects. *J Appl Physiol* 1992;73:2530-7.
130. Chrusch C, Sharma S, Unruh H, Bautista E, Duke K, Becker A, et al. Histamine H₃ receptor blockade improves cardiac function in canine anaphylaxis. *Am J Respir Crit Care Med* 1999;160:1142-9.
131. Schwartz LB, Lewis RA, Seldin D, Austen KF. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. *J Immunol* 1981;126:1290-4.
132. Schwartz LB, Schratz JJ, Vik D, Austen KF. Cleavage of human C₃ by human mast cell tryptase. *Fed Proc* 1982;41:487, A1270.
133. Ember JA, Hugli TE. Complement factors and their receptors. *Immunopharmacology* 1997;38:3-15.
134. Best N, Teisner B, Grudzinskas JG, Fisher MM. Classical pathway activation during an adverse response to protamine sulphate. *Br J Anaesth* 1983;55:1149-53.
135. Tobin MC, Karns BK, Anselmino LM, Thomas LL. Potentiation of human basophil histamine release by protamine: a new role for a polycation recognition site. *Mol Immunol* 1986;23:245-53.
136. Hobbhahn J, Habazettl H, Conzen P, Peter K. Komplikationen durch Protamin. Teil 1: Pharmakologie und Pathophysiologie. *Anaesthesist* 1991;40:365-74.
137. Regal JF, Fraser DG, Toth CA. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig. *J Pharmacol Exp Ther* 1993;267:979-88.
138. Jones HM, Matthews N, Vaughan RS, Stark JM. Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways. *Anaesthesia* 1982;37:629-33.
139. Stenson WF, Parker CW. Metabolites of arachidonic acid. *Clin Rev Allergy* 1983;1:369-84.
140. Farrukh IS, Michael JR, Summer WR, Adkinson NF, Jr., Gurtner GH. Thromboxane-induced pulmonary vasoconstriction: involvement of calcium. *J Appl Physiol* 1985;58:34-44.

141. Miyahara T, Shibamoto T, Wang HG, Koyama S. Role of circulating blood components and thromboxane in anaphylactic vasoconstriction in isolated canine lungs. *J Appl Physiol* 1997;83:1508-16.
142. Cooper JD, McDonald JW, Ali M, Menkes E, Masterson J, Klement P. Prostaglandin production associated with the pulmonary vascular response to complement activation. *Surgery* 1980;88:215-21.
143. Walch L, Norel X, Gascard JP, Brink C. Cysteinyl-leukotriene receptors in pulmonary vessels [In Process Citation]. *J Physiol Pharmacol* 1999;50:567-73.
144. Pinckard RN, Farr RS, Hanahan DJ. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. *J Immunol* 1979;123:1847-57.
145. Jancar S, Sirois MG, Carrier J, Braquet P, Sirois P. PAF induces rat plasma extravasation and releases eicosanoids during anaphylaxis. *Inflammation* 1991;15:347-54.
146. Mourad FH, O'Donnell LJ, Ogutu E, Dias JA, Farthing MJ. Role of 5-hydroxytryptamine in intestinal water and electrolyte movement during gut anaphylaxis. *Gut* 1995;36:553-7.
147. Vignon H. Réactions de type histaminique observées au cours de l'anesthésie générale. *Ann Anesthésiol Fr* 1976;17:1-8.
148. Ghannem M, Marsepoil T, Godard S, HO P, Montheli J, Laine, R. Réaction anaphylactique avec spasme coronarien au décours d'une coronarographie. *Ann Cardiol Angéiol* 1993;42:416-8.
149. Cooper D. Cardiac dysfunction during anaphylaxis in patients. *App Cardiopulm Pathophysiol* 1993;5:9-18.
150. Bermejo N, Guéant JL, Mata E, Gerard P, Moneret-Vautrin DA, Laxenaire MC. Platelet serotonin is a mediator potentially involved in anaphylactic reaction to neuromuscular blocking drugs. *Br J Anaesth* 1993;70:322-5.
151. Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5-HT₃ antagonists? *Br J Anaesth* 1999;82:439-41.
152. Smith PL, Kagey-Sobotka A, Bleecker ER, Traystman R, Kaplan AP, Gralnick H, et al. Physiologic manifestations of human anaphylaxis. *J Clin Invest* 1980;66:1072-80.
153. Barnes PJ. Effect of bradykinin on airway function. *Agents Actions Suppl* 1992;38:432-8.
154. Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis. Coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. *Circ Res* 1995;76:434-40.

155. Schuligoi R, Amann R, Donnerer J, Peskar BA. Release of calcitonin gene-related peptide in cardiac anaphylaxis. *Naunyn Schmiedebergs Arch Pharmacol* 1997;355:224-9.
156. Amir S, English AM. An inhibitor of nitric oxide production, NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock. *Eur J Pharmacol* 1991;203:125-7.
157. Mitsuhashi H, Saitoh J, Takeuchi H, Hasome N, Horiguchi Y, Shimizu R. Production of nitric oxide in anaphylaxis in rabbits. *Shock* 1994;2:381-4.
158. Osada S, Ichiki H, Oku H, Ishiguro K, Kunitomo M, Semma M. Participation of nitric oxide in mouse anaphylactic hypotension. *Eur J Pharmacol* 1994;252:347-50.
159. Saitoh J, Mitsuhashi H, Takeuchi H, Hasome N, Shimizu R. In vivo production of nitric oxide in the canine heart in IgE-mediated anaphylaxis. *Shock* 1996;6:66-70.
160. Abend Y, Ashkenazy Y, Witzling V, Feigl D, Geltner D, Moshonov S, et al. Nitric oxide: a mediator in anaphylactic shock in guinea-pigs. *J Basic Clin Physiol Pharmacol* 1996;7:57-69.
161. Mitsuhashi H, Takeuchi H, Saitoh J, Hasome N, Horiguchi Y, Shimizu R. An inhibitor of nitric oxide synthase, N omega-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. *Shock* 1995;3:447-53; discussion 454.
162. Mitsuhashi H, Saitoh J, Hasome N, Takeuchi H, Horiguchi Y, Shimizu R. Nitric oxide synthase inhibition is detrimental to cardiac function and promotes bronchospasm in anaphylaxis in rabbits. *Shock* 1995;4:143-8.
163. Pallapies D, Thelen K, Dembinska-Kiec A, Simmet T, Peskar BA. Effect of 3-morpholinosydnonimine (SIN-1), NG-nitro-L-arginine (NNA) and NG-monomethyl-L-arginine (NMMA) on isolated anaphylactic guinea-pig hearts. *Agents Actions Suppl* 1992;37:114-9.
164. Thelen KI, Dembinska-Kiec A, Pallapies D, Simmet T, Peskar BA. Effect of 3-morpholinosydnonimine (SIN-1) and NG-nitro-L-arginine (NNA) on isolated perfused anaphylactic guinea-pig hearts. *Naunyn Schmiedebergs Arch Pharmacol* 1992;345:93-9.
165. Dewachter P, Vassiliou M, Saunier CG, Hartemann D, Peslin R, Laxenaire MC. Effect of the inhibitor of NO synthase, Ng-nitro-L-arginine methyl ester, on histamine-induced bronchospasm in the rabbit. *Acta Physiol Scand* 1997;161:47-53.